Research programme: diabetes and obesity therapeutics - Hanmi Pharmaceutical

Drug Profile

Research programme: diabetes and obesity therapeutics - Hanmi Pharmaceutical

Alternative Names: DGAT - Hanmi; DGAT1 inhibitor - Hanmi; GPR119 agonist - Hanmi; HM 47000

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetes mellitus; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in South Korea
  • 16 Jul 2016 No recent reports of development identified for research development in Obesity in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top